Literature DB >> 3956003

Chondrosarcoma.

J H Healey, J M Lane.   

Abstract

Chondrosarcoma is a malignant cartilage-forming tumor that affects predominently the middle-aged population. There are three histologic grades, but differentiation of Grade I tumors from enchondromas can be difficult. The measurement of polypoidy (augmented chromosomal content per cell) appears to offer a method of segregation of benign from low-grade from high-grade tumors. With the exception of the high-grade spindle elements, current chemotherapy does not appear to affect chondrosarcomas. Retinoic acid, however, by enhancing lysosomal enzyme release, may be a potential efficacious therapeutic agent. Enhanced tumor staging as provided by the computed tomographic (CT) scan has demonstrated the boundaries for wide surgical excisions, most notably internal hemipelvectomies for low- and moderate-grade pelvic chondrosarcomas. Currently, low-grade chondrosarcomas have an overall five-year survival of 65%--85% in contradistinction to 15% for the highest grade chondrosarcomas.

Entities:  

Mesh:

Year:  1986        PMID: 3956003

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  14 in total

1.  Recurrent chondrosarcoma of the cranial base: a durable response to ifosfamide-doxorubicin chemotherapy.

Authors:  R V La Rocca; K W Morgan; K Paris; T R Baeker
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

2.  Chondrosarcoma of bone: lessons from 46 operated cases in a single institution.

Authors:  Olavo Pires de Camargo; André Mathias Baptista; Marcelo Junqueira Atanásio; Daniel Reis Waisberg
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

3.  Orthopaedic tumors: What problems are we solving, and are universities and major medical centers doing enough?

Authors:  Mohamed Mediouni; Daniel R Schlatterer
Journal:  J Orthop       Date:  2017-05-04

4.  Intralesional treatment versus wide resection for central low-grade chondrosarcoma of the long bones.

Authors:  Edwin F Dierselhuis; Krista A Goulding; Martin Stevens; Paul C Jutte
Journal:  Cochrane Database Syst Rev       Date:  2019-03-07

5.  Loss of β-catenin induces multifocal periosteal chondroma-like masses in mice.

Authors:  Leslie Cantley; Cheri Saunders; Marta Guttenberg; Maria Elena Candela; Yoichi Ohta; Rika Yasuhara; Naoki Kondo; Federica Sgariglia; Shuji Asai; Xianrong Zhang; Ling Qin; Jacqueline T Hecht; Di Chen; Masato Yamamoto; Satoru Toyosawa; John P Dormans; Jeffrey D Esko; Yu Yamaguchi; Masahiro Iwamoto; Maurizio Pacifici; Motomi Enomoto-Iwamoto
Journal:  Am J Pathol       Date:  2012-12-25       Impact factor: 4.307

6.  No recurrences in selected patients after curettage with cryotherapy for grade I chondrosarcomas.

Authors:  Badio S Souna; Nicolas Belot; Hélène Duval; Frantz Langlais; Hervé Thomazeau
Journal:  Clin Orthop Relat Res       Date:  2010-01-07       Impact factor: 4.176

7.  Retroperitoneal mesenchymal chondrosarcoma mimicking a large retroperitoneal sacral schwannoma.

Authors:  Giancarlo D'Andrea; Emanuela Caroli; Michela Giuli Capponi; Francesco Scicchitano; Mattia Falchetto Osti; Carlo Bellotti; Luigi Ferrante
Journal:  Neurosurg Rev       Date:  2007-10-03       Impact factor: 3.042

8.  Two-stage therapy in the treatment of sacral tumors.

Authors:  P Wuisman; A Härle; H H Matthiass; A Roessner; R Erlemann; M Reiser
Journal:  Arch Orthop Trauma Surg       Date:  1989       Impact factor: 3.067

9.  Chordoma and chondrosarcoma gene profile: implications for immunotherapy.

Authors:  Joseph H Schwab; Patrick J Boland; Narasimhan P Agaram; Nicholas D Socci; Tianhua Guo; Gary C O'Toole; Xinhui Wang; Elena Ostroumov; Christopher J Hunter; Joel A Block; Stephen Doty; Soldano Ferrone; John H Healey; Cristina R Antonescu
Journal:  Cancer Immunol Immunother       Date:  2008-07-19       Impact factor: 6.968

10.  Survival and prognostic factors in chondrosarcoma: results in 115 patients with long-term follow-up.

Authors:  Dimosthenis Andreou; Sebastian Ruppin; Sebastian Fehlberg; Daniel Pink; Mathias Werner; Per-Ulf Tunn
Journal:  Acta Orthop       Date:  2011-11-09       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.